Belinda R. Avalos, M.D.
Dr. Avalos graduated from The Ohio State University College of Medicine. She subsequently completed a residency in Internal Medicine at The Ohio State University, followed by a fellowship in hematology and medical oncology at The University of Washington and UCLA. She returned to Ohio State, where she quickly rose through the ranks to Full Professor of Medicine. In 2012, she moved to the Levine Cancer Institute in Charlotte, NC, where she currently serves as Vice Chair of the Department of Hematologic Oncology and Blood Disorders, Medical Director of the Transplant and Cellular Therapy Laboratory, and Director of Research. She is also a Professor of Medicine at the University of North Carolina, Chapel Hill. Dr. Avalos is an expert on receptor physiology and cell signaling, with a major focus on CSF3R (G-CSFR) mutations and leukemogenesis. Her laboratory was the first to demonstrate that CSF3R truncation mutations in patients with AML delete a critical receptor internalization domain that results in prolonged ligand-induced cell signaling and enhanced cell growth. Dr. Avalos has been a major proponent of increasing diversity and inclusiveness in medicine. As the past Chair of the American Society of Hematology’s (ASH’s) Committee on Promoting Diversity, she oversaw the creation of numerous awards to enable underrepresented minority medical students and trainees to undertake research projects in hematology to increase the recruitment and retention of underrepresented minorities into the field of hematology. She currently serves on the ASH Executive Committee and is co-Chair of the newly created Diversity and Inclusion Committee of the American Society of Transplant and Cellular Therapy. She has been actively involved in medical education, and served as a mentor for more than 100 junior faculty, fellows, housestaff, and medical and undergraduate students.